Clinical Trial Update: Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.

View source ↗

Summary

Pfizer-sponsored real-world study assesses patterns of care and outcomes in AfME patients with metastatic renal cell carcinoma treated with first-line sunitinib…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Renal Cell Carcinoma | Status: TERMINATED | Results posted: 2024-05-10